(lp0
S"Rigel Pharmaceuticals Is Worth A Timely Look Seeking Alpha - Mar 27, 2017 Rigel Pharmaceuticals  is pursuing a novel mechanism of action with its drug, fostamatinib. Spleen Tyrosine Kinase  inhibitors have shown positive results in studies analyzing allergies, autoimmune diseases, and immune cell&nbsp;...Analyst's Predictions on Allergan plc , Rigel Pharmaceuticals, Inc.  - StockNewsJournalRigel Pharmaceuticals, Inc.  Given Consensus Rating of Buy by Brokerages - Chaffey Breeze"
p1
aS"Why Rigel Pharmaceuticals, Inc. Got Hammered Today Motley Fool - Oct 20, 2016 Rigel Pharmaceuticals  is down 23% at 11:30 a.m. EDT after the company reported a second phase 3 clinical trial testing for its spleen tyrosine kinase inhibitor, fostamatinib, in patients with adult chronic/persistent immune ...Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term ... - PR Newswire Stock Update : Here's Why Rigel Pharmaceuticals, Inc. Shares Are ... - Smarter Analyst"
p2
aS"Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing ... PR Newswire  - Jan 16, 2017 SOUTH SAN FRANCISCO, Calif., Jan. 16, 2017 /PRNewswire/ -- Rigel Pharmaceuticals  today announced that on January 3, 2017 and January 16, 2017 the Compensation Committee of Rigel's Board of Directors approved the grant of&nbsp;..."
p3
aS'Are Rigel Pharmaceuticals, Inc.  Stock Technicals Favorable? USA Commerce Daily - 12 hours ago With all other things going on, Rigel Pharmaceuticals, Inc.  has been on a run - rising 41.74 percent in just three months.'
p4
aS"Here's Why Rigel Pharmaceuticals, Inc. is Skyrocketing Today Motley Fool - Aug 30, 2016 What: Shareholders of Rigel Pharmaceuticals , a small-cap clinical stage biopharma, are having a pleasant Tuesday.BMO Thinks Rigel's Fostamatinib Market Opportunity Will Be Further Validated - BenzingaWhy Rigel Pharma Is Making a Run - 24/7 Wall St."
p5
aS'Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year ... PR Newswire  - Feb 28, 2017 SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.  today announced that it will report its fourth quarter and year end 2016 financial results after market close on Tuesday, March 7, 2017.Rigel Pharmaceuticals Inc.  Moves Lower on Volume Spike for February 28 - Equities.com'
p6
aS"Rigel Pharmaceuticals Inc: Hits 4-month high Times of India - Mar 8, 2017 ... ** Drug developer's shares rise as much as 14.2 pct to $2.98 - their highest intraday level since mid-November. ** Rigel on Tuesday indicates it is on track to submit a U.S. marketing application in Q1 for its experimental drug fostamatinib to ..."
p7
aS"Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and ... PR Newswire  - Mar 7, 2017 &quot;We believe that the favorable safety profile and demonstrated efficacy of fostamatinib may make it an excellent treatment option for patients with chronic ITP,&quot; said Raul Rodriguez, Rigel's president and chief executive officer. &quot;The company expects ...Rigel Pharmaceuticals Inc.  Plunges 6.99% on March 06 - Equities.comStock Returns: Rigel Pharmaceuticals Inc  is Beating Natera Inc ... - CML News"
p8
aS"Fostamatinib Study Results Continue to Trend Positive PR Newswire  - Jan 30, 2017 30, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.  today announced updates from the clinical program of fostamatinib in patients with chronic immune thrombocytopenic purpura .Rigel Pharmaceuticals  Stock: NDA Coming Soon! - CNA Finance Rigel's fostamatinib still positive in late-stage extension study; shares ... - Seeking Alpha"
p9
aS'Rigel Pharmaceuticals Inc.  Plunges 8.11% on March 21 Equities.com - Mar 21, 2017 Rigel Pharmaceuticals Inc.  had a rough trading day for Tuesday March 21 as shares tumbled 8.11%, or a loss of $-0.24 per share, to close at $2.72.'
p10
a.